Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03514407 · ClinicalTrials.gov registry record · Phase 1
A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT03514407 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 25 participants.
The verdict
NCT03514407, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and preliminary antitumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.
Interventions
- DRUG INCB059872
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-06-27 |
| Est. Completion | 2020-06-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03514407
The ClinicalTrials.gov registry entry for NCT03514407 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB059872 is the first listed.
NCT03514407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03514407 about?
NCT03514407 is a clinical study titled "A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma". The purpose of this study is to evaluate the safety and preliminary antitumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.
What is the current status of trial NCT03514407?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2018-06-27. Estimated completion is 2020-06-25.
What interventions are being tested in trial NCT03514407?
The interventions under investigation include: INCB059872 (DRUG).
Who is sponsoring clinical trial NCT03514407?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.